We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00646126
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : March 28, 2008
Information provided by:

Study Description
Brief Summary:
The malaria parasite Plasmodium falciparum remains at sub-patent level throughout the dry season in areas of seasonal malaria transmission. Targeting this parasite reservoir before the transmission season could be a good strategy for malaria control. We are conducting a randomized double blind placebo controlled mass drug administration trial in eight village to clear the dry season low level parasitaemia with an ultimate aim of controlling malaria in eastern Sudan.

Condition or disease Intervention/treatment Phase
Plasmodium Falciparum Asymptomatic Parataemia Sub Patent Parasitaemia Drug: Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS) Drug: placebo tablet similar to active drug in shape and size Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Validation of the Use of Istope-Based Molecular Techniques for Malaria Control
Study Start Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1
1:Active comparator sulfadoxine-pyrimethamine plus artesunate
Drug: Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)
Standard three day regimen
Placebo Comparator: 2
2:placebo comparator
Drug: placebo tablet similar to active drug in shape and size
Dosage similar to active drug(standard three days regimen)

Outcome Measures

Primary Outcome Measures :
  1. Parsitaemia detected during the transmission season among dry season PCR negative persons in the intervention and control villages [ Time Frame: October to December 2006 ]

Secondary Outcome Measures :
  1. 1. Malaria prevalence during the transmission season 2. Frequency of mutation in drug resistance genes

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • All residents of the 8 villages

Exclusion Criteria:

  • Pregnancy
  • History of allergy to sulfa drugs
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00646126

Tropical Medicine Research Institute
Khartoum, Sudan, 11111
Sponsors and Collaborators
Tropical Medicine Research Institute
London School of Hygiene and Tropical Medicine
International Atomic Energy Agency
Principal Investigator: Badria B El Sayed, PhD,MSc,BSc Tropical Medicine Research Institute
More Information

ClinicalTrials.gov Identifier: NCT00646126     History of Changes
Other Study ID Numbers: SUD 6/025
First Posted: March 28, 2008    Key Record Dates
Last Update Posted: March 28, 2008
Last Verified: August 2005

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Systemic Inflammatory Response Syndrome
Pathologic Processes
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Renal Agents